Cambridge Scientists Build Miniature Human Organs to Cut Animal Drug Testing

Researchers at the Cambridge Stem Cell Institute are creating a library of standardized, validated organoids—tiny three-dimensional clusters of human cells grown from National Health Service (NHS) patients. The aim is to use these human-derived models for early-stage drug testing, allowing scientists to assess efficacy and toxicity directly on patient tissue rather than on animals. The effort is part of the UK government’s plan to fast-track the reduction of animal use in biomedical research.

Cambridge Scientists Grow Miniature Human Organs to End Animal Drug Testing The Guardian

The project is funded with £20 million from the Medical Research Council, supplemented by a £2 million Innovate UK award for nine related projects targeting reductions in the use of dogs and monkeys. Researchers will initially focus on organoids for inflammatory bowel diseases, with future work expanding to tumour and brain models. By providing a shared resource to academia and the pharmaceutical industry, the initiative seeks to replace traditional animal tests that can involve 50 to 100 animals for heart-safety assessments.

The Guardian

• Historically, more than 90 % of drug candidates that pass animal testing fail in human trials.

The Guardian

• In the UK, 2.54 million animal-testing procedures were recorded last year, a 3.8 % decline from 2024, with over 90 % involving mice, rats, fish or birds and 1 % using protected species such as cats, dogs, horses and monkeys.

The Guardian

• Organoids smaller than a millimetre have been shown to replicate key organ functions and disease responses, offering a more predictive platform for drug screening.

Cambridge Scientists Grow Miniature Human Organs to End Animal Drug Testing

Matthias Zilbauer, clinical professor of paediatric gastroenterology at the Cambridge Stem Cell Institute, emphasised that many human diseases either do not occur in animals or manifest differently, limiting the relevance of animal models. He argued that organoid-based testing can identify which treatments work for specific patient pathologies, potentially lowering failure rates in later clinical phases. The initiative aligns with the Keir Starmer government’s “new approach methodologies” strategy, which promotes organ-on-a-chip systems and artificial-intelligence tools to modernise drug development.

The GuardianCambridge Scientists Grow Miniature Human Organs to End Animal Drug Testing

• “It’s going to have a major impact on the numbers of animals used and the way we develop new drugs in the future,” — Matthias Zilbauer, professor

The Guardian

• “A lot of human diseases either do not occur in animals or occur in a different way because they’re not human,” — Matthias Zilbauer, professor

The Guardian

• “One of the huge advantages of organoids, organs-on-a-chip and other in vitro microphysiological systems is that, unlike animal models, they have real potential to deliver the promise of truly personalised medicine for individual patients. It is all very exciting.” — Dr Juliet Dukes

The Guardian